Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041240
Abstract: Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018… read more here.
Keywords: therapeutic optimization; lutetium 177; safety therapeutic; based radiopharmaceuticals ... See more keywords